{
    "nct_id": "NCT03269994",
    "official_title": "A Phase III Multicenter, Open Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy",
    "inclusion_criteria": "* Age >/= 18 years\n* Patients undergoing elective pancreatoduodenectomy (PD) for any diagnosis/indication\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients undergoing a minimally invasive PD, such as laparoscopic or robotic PD\n* Patients with known and documented allergies to any of the penicillins, cephalosporins, or Î²-lactamase inhibitors\n* Patients who are otherwise ineligible to receive the antibiotics in this study\n* Patients highly unlikely to undergo PD according to the surgeon's judgment, such as conditions amenable to pancreas enucleation, ampullectomy, etc.\n* Patients with long-term glucocorticosteroid use. The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)\n* Patients unable to provide informed consent\n* Creatinine clearance (CrCl) </= 40 mL/min\n* Patients receiving hemodialysis or peritoneal dialysis\n* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test\n* Patients with a known bacterial infection present at the time of surgery or who received antimicrobial therapy within 7 days prior to surgery",
    "miscellaneous_criteria": ""
}